A drug-first approach

Drug discovery with a head start

Tavros employs an integrated high-throughput functional genomics discovery platform to uncover unique weaknesses in cancer cells that are exposed by drug treatment. These context-specific vulnerabilities point us to a clear clinical path for novel drug development with the knowledge of predictive biomarkers and optimal drug combinations that improve therapeutic response. We use this dynamic discovery engine to identify first-in-class drug targets with a clear path forward to the clinic to get the right drugs to the right patients, faster.

Patient stratification biomarkers improve oncology clinical trial success rate by >50%

Oncology drugs are typically given in combination

Starting with vetted, druggable targets dramatically reduces time to IND

Tavros’ drug discovery programs are focused on using our drug-first functional genomics screening approach to discover novel drug targets in strategic, underserved areas in cancer biology.

Connect with Tavros